首页 | 本学科首页   官方微博 | 高级检索  
检索        


Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
Authors:Brendon L Neuen  Toshiaki Ohkuma  Bruce Neal  David R Matthews  Dick de Zeeuw  Kenneth W Mahaffey  Greg Fulcher  Jaime Blais  Qiang Li  Meg J Jardine  Vlado Perkovic  David C Wheeler
Institution:1. The George Institute for Global Health, UNSW Sydney, Sydney, Australia;2. Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, Oxford, United Kingdom;3. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;4. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA;5. Royal North Shore Hospital, Sydney, Australia;6. Janssen Scientific Affairs, LLC, Titusville, NJ;7. Concord Repatriation General Hospital, Sydney, Australia;8. Centre for Nephrology, University College London, London, United Kingdom
Abstract:
><ol class=
  • Download : Download high-res image (392KB)
  • Download : Download full-size image
  • Keywords:Canagliflozin  cardiovascular outcomes  KDIGO  kidney outcomes  SGLT2 inhibitor  kidney disease trajectory  estimated glomerular filtration rate (eGFR)  urinary albumin-creatinine ratio (UACR)  chronic kidney disease (CKD)  CKD classification  albuminuria  renal function  adverse event  risk stratification  eGFR slope
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号